Literature DB >> 35611266

Updated Survival and Secondary Safety and Efficacy Analyses From CA 209-678: A Phase 2, Open-Label, Single-Center Study of Y90-Radioembolization in Combination With Nivolumab in Asian Patients With Advanced Hepatocellular Carcinoma.

.   

Abstract

Entities:  

Year:  2021        PMID： 35611266      PMCID： PMC9122048     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

1.  Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma.

Authors:  Chenyang Zhan; David Ruohoniemi; Krishna P Shanbhogue; Jason Wei; Theodore H Welling; Ping Gu; James S Park; Nabil N Dagher; Bedros Taslakian; Ryan M Hickey
Journal:  J Vasc Interv Radiol       Date:  2019-08-14       Impact factor: 3.464

2.  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Authors:  Andrew X Zhu; Richard S Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen L Chan; Jennifer Knox; Bruno Daniele; Andrea L Webber; Scot W Ebbinghaus; Junshui Ma; Abby B Siegel; Ann-Lii Cheng; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2018-06-03       Impact factor: 41.316

3.  Updated Survival and Secondary Safety and Efficacy Analyses From CA 209-678: A Phase 2, Open-Label, Single-Center Study of Y90-Radioembolization in Combination With Nivolumab in Asian Patients With Advanced Hepatocellular Carcinoma.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-11

Review 4.  Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives.

Authors:  Riad Salem; Vincenzo Mazzaferro; Bruno Sangro
Journal:  Hepatology       Date:  2013-10-04       Impact factor: 17.425
  4 in total
  3 in total

1.  Updated Survival and Secondary Safety and Efficacy Analyses From CA 209-678: A Phase 2, Open-Label, Single-Center Study of Y90-Radioembolization in Combination With Nivolumab in Asian Patients With Advanced Hepatocellular Carcinoma.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-11

2.  Highlights in Hepatocellular Carcinoma From the 2021 European Society for Medical Oncology Congress: Commentary.

Authors:  Catherine T Frenette
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-11

Review 3.  Trial Designs for Integrating Novel Therapeutics into the Management of Intermediate-Stage Hepatocellular Carcinoma.

Authors:  Yung-Yeh Su; Yi-Sheng Liu; Chin-Fu Hsiao; Chiun Hsu; Li-Tzong Chen
Journal:  J Hepatocell Carcinoma       Date:  2022-06-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.